natgillin/translations-raw huggingface dataset:
The CVMP concluded that the benefits of ZULVAC 1+8 Ovis outweigh the risks for the prevention of viraemia caused by bluetongue virus, serotypes 1 and 8 in sheep from 1.5 months of age.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila ZULVAC 1+8 Ovis pri preprečevanju viremije, ki jo povzročata serotipa 1 in 8 virusa bolezni modrikastega jezika pri ovcah, starejših od enega meseca in pol, večje od z njim povezanih tveganj.
The withdrawal period for ZULVAC 1+8 Ovis for meat and milk is zero days.
Karenca za cepivo ZULVAC 1+8 Ovis za meso in mleko je nič dni.
ZULVAC 1+8 Ovis is a vaccine that contains inactivated (killed) bluetongue serotypes 1 and 8 viruses as the active substance.
Zdravilo ZULVAC 1+8 Ovis je cepivo, ki kot zdravilno učinkovino vsebuje inaktivirana (uničena) serotipa 1 in 8 virusa bolezni modrikastega jezika.
What is the risk associated with ZULVAC 1+8 Ovis?
Kakšna tveganja so povezana z zdravilom ZULVAC 1+8 Ovis?
Why has ZULVAC 1+8 Ovis been approved?
Zakaj je bilo zdravilo ZULVAC 1+8 Ovis odobreno?
How has ZULVAC 1+8 Ovis been studied?
Kako je bilo zdravilo ZULVAC 1+8 Ovis raziskano?
The virus exists in several forms (serotypes) throughout the world; the types used in ZULVAC 1+8 Ovis are serotypes 1 and 8.
Virus obstaja v različnih oblikah (serotipih) po vsem svetu.
What is ZULVAC 1+8 Ovis?
Kaj je zdravilo ZULVAC 1+ 8 Ovis?
How does ZULVAC 1+8 Ovis work?
Kako zdravilo ZULVAC 1+8 Ovis deluje?
What is ZULVAC 1+8 Ovis used for?
Za kaj se zdravilo ZULVAC 1+8 Ovis uporablja?
This means that it was not possible to obtain complete information about ZULVAC 1+8 Ovis at the time of the initial authorisation.
To pomeni, da ob prvotni odobritvi ni bilo mogoče pridobiti vseh podatkov o njem.
It is used for dogs and cats.
Uporablja se za pse in mačke.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea.europa.eu http://www.emea.europa.eu©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
7 Westferry Circus, Canary Wharf, London E14 4HB, UK (44-20) 74 18 84 00 Faks (44-20) 74 18 84 16 E. pošta: mail@emea.europa.eu http://www.emea.europa.eu EMEA 2007 Reprodukcija in/ali distribucija tega dokumenta je odobrena za nekomercialne namene, dokler je EMEA priznana kot avtor dokumenta.
These symptoms return to normal in the week after the last injection.
Ti simptomi izzvenijo v tednu po zadnji injekciji.
• hyperthermia (increased temperature, 3-6 hours after injection)
• hipertermija (povišana telesna temperatura, ki se pojavi od 3 do 6 ur po injekciji),
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) VIRBAGEN OMEGA EPAR summary for the public
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) VIRBAGEN OMEGA Povzetek EPAR za javnost
There may be a slight decrease in white blood cells, platelets and red blood cells, and a rise in the concentration of alanine aminotransferase (a liver enzyme).
Pojavi se lahko blag padec števila belih krvničk, trombocitov in rdečih krvničk in povišana koncentracija alanin aminotransferaze (jetrnega encima).
The mortality rate for dogs treated with Virbagen Omega was 4.4-6.4 times lower than that of the untreated animals.
Smrtnost pri psih, ki so jih zdravili z zdravilom Vibragen Omega je bila od 4,4 do 6,5 krat nižja kot pri nezdravljenih živalih.
Interferons are a family of naturally occurring proteins that are produced in response to viral infections.
Interferoni so družina v telesu naravno prisotnih beljakovin, ki nastajajo kot odziv na virusne okužbe.
• soft faeces to mild diarrhoea, in cats only
• mehko blato do blaga diareja, samo pri mačkah,
The main measure of effectiveness was the mortality rate compared with dogs that had not been treated.
Glavno merilo učinkovitosti je bila njihova smrtnost v primerjavi s smrtnostjo psov, ki jih niso zdravili.
The European Commission granted a marketing authorisation valid throughout the European Union, for Virbagen Omega to Virbac SA on 6 November 2001.
Evropska Komisija je dovoljenje za promet z zdravilom Virbagen Omega, veljavno po vsej Evropski uniji, odobrila družbi Virbac SA dne 6. novembra 2001.
• transitory vomiting
• bruhanje,
Information on the prescription status of this product may be found on the labelling.
Podatki o predpisovanju tega zdravila so navedeni na ovojnini zdravila.
Cats: The suspension should be injected subcutaneously (under the skin) once daily for 5 consecutive days.
Mačke: Suspenzijo morate vbrizgati subkutano (pod kožo) enkrat dnevno 5 dni zapored.
The injection of Virbagen Omega may cause the following temporary symptoms in dogs and cats:
Injekcija zdravila Vibragen Omega lahko pri psih in mačkah povzroči naslednje prehodne simptome:
Two further 5-day treatments must be carried out at 14 days, and 60 days after the first 5-day course.
Po 14 in 60 dneh od konca prvega zdravljenja morate izvesti še po eno dodatno, 5 dni trajajoče zdravljenje.
• fatigue during the treatment, in cats only
• utrujenost med zdravljenjem, samo pri mačkah.
Other information about Virbagen Omega:
Druge informacije o zdravilu Vibragen Omega:
The main measure of effectiveness was the mortality rate compared with cats that had not been treated and clinical signs after treatment.
Glavno merilo učinkovitosti je bila primerjava smrtnosti s smrtnostjo pri mačkah, ki jih niso zdravili, in klinični znaki po zdravljenju.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the doctor.
Če si zdravilo nenamerno vbrizgate, se takoj posvetujte z zdravnikom in mu pokažite Navodilo za uporabo ali ovojnino zdravila.
Dogs: The suspension should be injected intravenously (into a vein) once daily for 3 consecutive days.
Psi: Suspenzijo morate vbrizgati intravensko (v veno) enkrat dnevno 3 dni zapored.
Virbagen Omega 2.5 MU/kg was given intravenously for 3 days.
Zdravilo Vibragen Omega 2,5 ME/kg so dajali intravensko 3 dni.
In the population of cats (whether they were FeLV positive, FIV positive or co-infected by both viruses, there was a reduction of clinical signs over time, improving the quality of life of cats.
Pri populaciji mačk (okuženih s FeLV, FIV ali sočasno okuženih z obema virusoma) so opazili postopoma upadajočo prisotnost kliničnih znakov in izboljšanje kvalitete življenja mačk.
In the treatment of cats with FeLV, there was a reduction of clinical signs over 4 months and a reduction in the mortality rate.
Pri zdravljenju mačk s FeLV so v obdobju 4 mesecev opazili zmanjšanje prisotnosti kliničnih znakov in smrtnosti.
The dose is 1 MU/kg bodyweight.
Odmerek znaša 1 ME/kg telesne teže.
In cats infected by FIV, the mortality rate was low (5%) and was not changed by the treatment.
Pri mačkah okuženih s FIV je bila smrtnost nizka (5 %), zdravljenje pa nanjo ni imelo vpliva.
In non-anaemic cats, the mortality rate (50 %) was reduced by 20%.
Pri mačkah, ki niso bile slabokrvne, je smrtnost (50 %) padla za 20 %.
The dose is 2.5 MU/kg bodyweight.
Odmerek znaša 2,5 ME/kg telesne teže.
Virbagen Omega works by stimulating the immune system to attack the virus.
Zdravilo Vibragen Omega deluje, tako da imunski sistem spodbuja k uničevanju virusa.
What benefit has Virbagen Omega shown during the studies?
Kakšne koristi je zdravilo Virbagen Omega izkazalo med raziskavami?
The replacement omega interferon acts in the same way as naturally produced omega interferon.
Nadomestni omega interferon deluje na enak način kot naravno prisotni omega interferon.
Virbagen Omega is a lyophilisate (freeze dried pellet) and solvent that is made into a suspension for injection.
Zdravilo Vibragen Omega sestavljata liofilizat (zamrznjene in posušene pelete) in vehikel za pripravo suspenzije za injiciranje.
In anaemic cats, the mortality rate in cats infected by FeLV (about 60%) was reduced by about 30%.
Pri slabokrvnih mačkah okuženih s FeLV je smrtnost (okoli 60 %) padla za približno 30 %.
The active substance of Virbagen Omega, omega interferon, is produced by a method known as ‘recombinant technology'.
Zdravilna učinkovina zdravila Virbagen Omega je omega interferon, ki se proizvaja z metodo imenovano "tehnologija rekombinantne DNA".
Why has Virbagen Omega been approved?
Zakaj je bilo zdravilo Virbagen Omega odobreno?
What is the risk associated with Virbagen Omega?
Kakšna tveganja so povezana z zdravilom Virbagen Omega?
Virbagen Omega is used to reduce mortality and clinical signs of parvovirosis (a highly contagious viral infection of dogs) in dogs from one month of age.
Zdravilo Vibragen Omega se uporablja za zmanjšanje smrtnosti in lajšanje kliničnih znakov parvoviroze (zelo nalezljive oblike virusne okužbe psov) pri psih, ki so stari en mesec ali več.
The omega interferon is made by a cell that has received a gene (DNA), which makes it able to produce omega interferon.
Proizvajajo ga celice, ki so prejele gen (DNK) za proizvajanje te učinkovine.
Virbagen Omega contains the active substance recombinant omega interferon of feline origin (from cats) at 5 MU/ vial or 10 MU/ vial.
Zdravilo Vibragen Omega vsebuje zdravilno učinkovino rekombinantni omega interferon mačjega izvora v količini 5 ME/vialo ali 10 ME/vialo.
They recommended that Virbagen Omega should be given a marketing authorisation.
Odbor je priporočil odobritev dovoljenja za promet z zdravilom Virbagen Omega.
Virbagen Omega has been studied in dogs (males and females) of at least five weeks old that were infected with parvovirosis.
Zdravilo Vibragen Omega so raziskovali pri psih (samcih in samicah) s parvovirozo, ki so bili stari vsaj pet tednov.
Virbagen Omega contains the active substance recombinant omega interferon.
Zdravilo Vibragen Omega vsebuje zdravilno učinkovino rekombinantni omega interferon.
The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Virbagen Omega are greater than any risks to reduce mortality and clinical signs of parvovirosis in dogs from one month of age, and to treat cats infected with FeLV (feline leukaemia virus) and/or FIV in non-terminal cats from the age of 9 weeks.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da so koristi zdravila Virbagen Omega pri manjšanju smrtnosti in lajšanju kliničnih znakov parvoviroze pri 1 ali več mesecev starih psih in pri 9 ali več mesecev starih mačkah s FeLV (virus mačje levkemije) in/ali FIV, ki niso v stadiju pred smrtjo, večje od z njim povezanih tveganj.
Virbagen Omega is also used to treat cats infected with FeLV (feline leukaemia virus) and/or FIV (feline immunodeficiency virus), in non-terminal cats from the age of 9 weeks.
Zdravilo Vibragen Omega se uporablja tudi za zdravljenje mačk okuženih s FeLV (virus mačje levkemije) in/ali FIV (virusa mačje imunske pomanjkljivosti) pri mačkah, ki niso v stadiju pred smrtjo in so stare 9 tednov ali več.
What is Virbagen Omega?
Kaj je zdravilo Vibragen Omega?
What is Virbagen Omega used for?
Za kaj se zdravilo Vibragen Omega uporablja?
Virbagen Omega has also been studied in the treatment of anaemic or non-anaemic cats infected with FeLV and/or FIV, from the age of 9 weeks.
Zdravilo Vibragen Omega so raziskovali tudi pri zdravljenju 9 tednov starih ali starejših slabokrvnih mačk in mačk z normalno krvno sliko, ki so bile okužene s FeLV in/ali FIV.
How has the effectiveness of Virbagen Omega been studied?
Kako je bilo zdravilo Virbagen Omega raziskano?
How does Virbagen Omega work?
Kako zdravilo Virbagen Omega deluje?
{mm/yyyy}
{MM/LLLL}
This leaflet was last revised in { mm/yyyy}
Navodilo je bilo nazadnje revidirano { MM/LLLL}.
To avoid this interference, PANTOZOL Control treatment should be stopped for at least 5 days before CgA measurements (see section 5.1).
Da bi to preprečili, je treba vsaj pet dni pred meritvami CgA prekiniti zdravljenje z zdravilom PANTOZOL Control (glejte poglavje 5.1).
What PANTOZOL Control is and what it is used for What you need to know before you take PANTOZOL Control How to take PANTOZOL Control Possible side effects
Kaj je zdravilo PANTOZOL Control in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo PANTOZOL Control Kako jemati zdravilo PANTOZOL Control Možni neželeni učinki
Sleep disorders Depression (and all aggravations)
Psihiatrične motnje motnje spanja depresija (in vsa poslabšanja)
If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping PANTOZOL Control.
Če se pojavijo lezije, zlasti na koži, ki je izpostavljena soncu, in sočasna artralgija, mora bolnik takoj poiskati zdravniško pomoč, zdravstveni delavec pa mora razmisliti o prekinitvi zdravljenja z zdravilom PANTOZOL Control.
Disorientation (and all aggravations)
dezorientirano st (in vsa poslabšanja)
What PANTOZOL Control is and what it is used for
Kaj je zdravilo PANTOZOL Control in za kaj ga uporabljamo
What you need to know before you take PANTOZOL Control
Kaj morate vedeti, preden boste vzeli zdravilo PANTOZOL Control
Within each frequency grouping adverse reactions are presented in order of decreasing seriousness.
V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti.
A previous peri-postnatal study in rats at slightly lower doses found no adverse effects at 3 mg/kg compared with a low dose of 5 mg/kg in this study.
Pri predhodni peri-postnatalni študiji pri podganah pri nekoliko nižjih odmerkih, 3 mg/kg v primerjavi z nizkim odmerkom 5 mg/kg v tej študiji, ni bilo pojava neželenih učinkov.Raziskave niso odkrile zmanjšane plodnosti ali teratogenih učinkov.
See ‘Other medicines and PANTOZOL Control'.
Glejte “Druga zdravila in zdravilo PANTOZOL Control” v nadaljevanju.
PANTOZOL Control is available in Alu/Alu blisters with or without cardboard reinforcement.
Zdravilo PANTOZOL Control je na voljo v Alu/Alu pretisnih omotih s kartonsko oporo ali brez nje.
However, you may take PANTOZOL Control with antacids (e.g. magaldrate, alginic acid, sodium bicarbonate, aluminium hydroxide, magnesium carbonate, or combinations thereof), if needed.
Zdravilo PANTOZOL Control lahko po potrebi jemljete skupaj z antacidi (npr. magaldrat, alginska kislina, natrijev hidrogenkarbonat, aluminijev hidroksid, magnezijev karbonat ali kombinacije naštetih).
You may experience relief from your acid reflux and heartburn symptoms after just one day of treatment with PANTOZOL Control, but this medicine is not meant to bring immediate relief.
Simptomi kislega refluksa in zgage se lahko ublažijo že po enem dnevu zdravljenja z zdravilom PANTOZOL Control, vendar pa to zdravilo ni namenjeno za dosego takojšnjega olajšanja.
PANTOZOL Control contains the active substance pantoprazole, which blocks the ‘pump' that produces stomach acid.
Zdravilo PANTOZOL Control vsebuje zdravilno učinkovino pantoprazol, ki zavira “črpalko”, ki proizvaja želodčno kislino.
PANTOZOL Control should not be used during breast-feeding.
Zdravila PANTOZOL Control se med dojenjem ne sme uporabljati.
- reduced absorption of Vitamin B12, and Vitamin B12 deficiency if you already have low body stores of Vitamin B12 - fracture of your hip, wrist or spine, especially if you already suffer from osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).
Če zdravilo PANTOZOL Control prejemate daljše obdobje, lahko to povzroči dodatna tveganja, kot so: - zmanjšana absorpcija vitamina B12 in pomanjkanje vitamina B12, če že imate nizke telesne zaloge vitamina B12 - zlom kolka, zapestja ali hrbtenice, še posebej, če že trpite zaradi osteoporoze ali če jemljete kortikosteroide (ki lahko povečajo tveganje za osteoporozo).
PANTOZOL Control may reduce the absorption of active substances whose bioavailability is dependent on the gastric pH (e.g. ketoconazole).
Zdravilo PANTOZOL Control lahko zmanjša absorpcijo zdravilnih učinkovin, katerih biološka uporabnost je odvisna od pH želodčnega soka (npr. ketokonazol).
What PANTOZOL Control looks like and contents of the pack The gastro-resistant tablets are yellow, oval, biconvex film-coated tablets imprinted with “P20” on one side.
Izgled zdravila PANTOZOL Control in vsebina pakiranja Gastrorezistentne tablete so rumene, ovalne, obojestransko izbočene filmsko obložene tablete z oznako “P20” na eni strani.
How to store PANTOZOL Control Contents of the pack and other information
Shranjevanje zdravila PANTOZOL Control Vsebina pakiranja in dodatne informacije
Do not take PANTOZOL Control with other medicines which limit the amount of acid produced in your stomach, such as another proton pump inhibitor (omeprazole, lansoprazole or rabeprazole) or an H2 antagonist (e.g. ranitidine, famotidine).
Ne jemljite zdravila PANTOZOL Control z drugimi zdravili, ki zavirajo izločanje želodčne kisline, kot so drugi zaviralci protonske črpalke (omeprazol, lansoprazol ali rabeprazol) ali antagonisti histaminskih receptorjev H2 (npr. ranitidin, famotidin).
PANTOZOL Control is not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy.
Zaradi nezadostnih podatkov o varnosti in učinkovitosti uporaba zdravila PANTOZOL Control pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva.
What PANTOZOL Control contains - The active substance is pantoprazole.
Kaj vsebuje zdravilo PANTOZOL Control - Zdravilna učinkovina je pantoprazol.
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Druga zdravila in zdravilo PANTOZOL Control Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
- You should not take PANTOZOL Control tablets for more than 4 weeks without consulting a doctor.
- PANTOZOL Control tablet ne smete jemati dlje kot 4 tedne brez posveta z zdravnikom.
You must not use PANTOZOL Control if you are taking HIV protease inhibitors.
Zdravila PANTOZOL Control ne smete uporabljati, če jemljete atazanavir.
How to take PANTOZOL Control
Kako jemati zdravilo PANTOZOL Control
If you take more PANTOZOL Control than you should Tell your doctor or pharmacist if you have taken more than the recommended dose.
Če ste vzeli večji odmerek zdravila PANTOZOL Control, kot bi smeli Če ste vzeli večji odmerek zdravila PANTOZOL Control, kot bi smeli, o tem obvestite svojega zdravnika ali farmacevta.
Do not take PANTOZOL Control tablets for more than 4 weeks without consulting your doctor.
Ne jemljite tablet PANTOZOL Control več kot 4 tedne brez posveta pri zdravniku.
Remember to also mention any other ill-effects like pain in your joints Your doctor may decide that you need some tests.
Ne pozabite omeniti morebitnih drugih neželenih učinkov, kot je bolečina v sklepih.
Do not take a double dose to make up for the forgotten dose.
Če ste pozabili vzeti zdravilo PANTOZOL Control Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
- if you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with SOMAC Control.
- Če se pojavi kožni izpuščaj, zlasti na koži, ki je izpostavljena soncu, čim prej obvestite zdravnika,
Control - if you are due to have a specific blood test (Chromogranin A) - if you are taking HIV protease inhibitors such as atazanavir, nelfinavir (for the treatment of
- ste naročeni na specifično preiskavo krvi (kromogranin A) - če jemljete zaviralce proteaze HIV, kot sta atazanavir; nelfinavir (za zdravljenje okužbe s HIV)
PANTOZOL Control is used for the short-term treatment of reflux symptoms (for example heartburn, acid regurgitation) in adults.
Zdravilo PANTOZOL Control uporabljamo za kratkotrajno zdravljenje simptomov refluksa (na primer zgaga, regurgitacija kisline) pri odraslih.
PANTOZOL Control 20 mg gastro-resistant tablets Pantoprazole
PANTOZOL Control 20 mg gastrorezistentne tablete pantoprazol
PANTOZOL Control 20 mg gastro-resistant tablets should not be chewed or crushed, and should be swallowed whole with liquid before a meal.
PANTOZOL Control 20 mg gastrorezistentnih tablet se ne sme žvečiti ali drobiti.
PANTOZOL Control 20 mg gastro-resistant tablets
PANTOZOL Control 20 mg gastrorezistentne tablete
PANTOZOL Control is indicated for short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.
Zdravilo PANTOZOL Control je indicirano za kratkotrajno zdravljenje simptomov refluksa (npr. zgaga, regurgitacija kisline) pri odraslih.
PANTOZOL Control should not be used by children and adolescents under 18 years of age due to a lack of safety information in this younger age group.
Zdravila PANTOZOL Control ne smejo jemati otroci in mladostniki, mlajši od 18 let.
Agranulocytosis Thrombocytopenia; Leukopenia,
Bolezni krvi in limfatičnega sistema agranulocitoza trombocitopeni ja, levkopenija, pancitopenija
- Frequency not known: hallucination, confusion (especially in patients with a history of these symptoms); decreased level of sodium in blood; decreased level of magnesium in blood, rash, possibly with pain in the joints;
- Pogostnost neznana (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti): halucinacije, zmedenost (še posebej pri bolnikih, ki so te bolezenske znake že imeli), zmanjšanje vrednosti natrija v krvi, zmanjšanje vrednosti magnezija v krvi, izpuščaj, lahko z bolečino v sklepih; občutek mravljinčenja, ščemenja, zbadanja, pekoč občutek ali odrevenelost, vnetje v debelem črevesu, ki povzroča dolgotrajno vodeno drisko.
Stevens-Johnson syndrome; Lyell syndrome;
StevensJohnsonov sindrom, Lyellov sindrom, multiformni eritem, fotosenzitivnost, subakutni kožni eritematozni lupus (glejte poglavje 4.4)
Hyperlipidaemias and lipid increases (triglycerides, cholesterol);
Presnovne in prehranske motnje hiperilipidemije in zvišana vrednost lipidov (trigliceridi, holesterol), spremembe telesne mase hiponatriemija, hipomagneziemij a, hipokalciemija
Do not take PANTOZOL Control: - if you are allergic to pantoprazole or to any of the other ingredients of this medicine (listed in section 6) - if you are taking HIV protease inhibitors such as atazanavir; nelfinavir (for the treatment of
Ne jemljite zdravila PANTOZOL Control - če ste alergični na pantoprazol ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Other medicines and PANTOZOL Control
Shranjevanje zdravila PANTOZOL Control
Liver enzymes increased (transaminases, γ-GT)
Bolezni jeter, žolčnika in žolčevodov zvišana vrednost jetrnih encimov (aminotransferaze, γ-GT)
PANTOZOL Control has no or negligible influence on the ability to drive and use machines.
Zdravilo PANTOZOL Control nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev, vendar pa se lahko pojavijo neželeni učinki, kot so omotica in motnje vida (glejte poglavje 4.8).
feeling of tingling, prickling, pins and needles, burning sensation or numbness, inflammation in the large bowel, that causes persistent watery diarrhoea.
driska, navzea / bruhanje, napihovanje in napenjanje v trebuhu, zaprtost, suha usta, bolečine in neugodje v trebuhu mikroskopski kolitis
Stop taking PANTOZOL Control when you are completely symptom-free.
Ko simptomi bolezni popolnoma minejo, zdravilo PANTOZOL Control nehajte jemati.
The full EPAR for Aerivio Spiromax can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Aerivio Spiromax je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Aerivio Spiromax.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Aerivio Spiromax.
This means that Aerivio Spiromax is similar to a ‘reference medicine' called Seretide Diskus (also known as Seretide Accuhaler), which contains the same active substances.
To pomeni, da je podobno „referenčnemu zdravilu“, in sicer zdravilu Seretide Diskus (znanemu tudi kot Seretide Accuhaler), ki vsebuje isti zdravilni učinkovini.